Nav: Home

Pain in the neck

March 13, 2017

For millions of sufferers, there is nothing more debilitating than chronic back or joint pain. It can feel like a lifetime of misery.

But researchers led by University of Utah bioengineering assistant professor Robby Bowles have discovered a way to curb chronic pain by modulating genes that reduce tissue- and cell-damaging inflammation.

"This has applications for many inflammatory-driven diseases," Bowles says. "It could be applied for arthritis or to therapeutic cells that are being delivered to inflammatory environments that need to be protected from inflammation."

The team's discovery was published in a new paper this month, "CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments," in a special issue of Tissue Engineering. University of Utah bioengineering doctoral student, Niloofar Farhang, co-authored the study, which is a collaborative project between the University of Utah, Duke University and Washington University in St. Louis.

In chronic back pain, for example, slipped or herniated discs are a result of damaged tissue when inflammation causes cells to create molecules that break down tissue. Typically, inflammation is nature's way of alerting the immune system to repair tissue or tackle infection. But chronic inflammation can instead lead to tissue degeneration and pain.

Bowles' team is using the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) system -- new technology of modifying human genetics -- to stop cell death and keep the cells from producing molecules that damage tissue and result in chronic pain. But it doesn't do this by editing or replacing genes, which is what CRISPR tools are typically used for. Instead, it modulates the way genes turn on and off in order to protect cells from inflammation and thus breaking down tissue.

"So they won't respond to inflammation. It disrupts this chronic inflammation pattern that leads to tissue degeneration and pain," Bowles says. "We're not changing what is in your genetic code. We're altering what is expressed. Normally, cells do this themselves, but we are taking engineering control over these cells to tell them what to turn on and turn off."

Now that researchers know they can do this, doctors will be able to modify the genes via an injection directly to the affected area and delay the degeneration of tissue. In the case of back pain, a patient may get a discectomy to remove part of a herniated disc to relieve the pain, but tissue near the spinal cord may continue to breakdown, leading to future pain. This method could stave off additional surgeries by stopping the tissue damage.

"The hope is that this stops degeneration in its tracks, and the patient could avoid any future surgeries," Bowles says. "But it's patient to patient. Some might still need surgery, but it could delay it."

So far, the team has developed a virus that can deliver the gene therapy and has filed a patent on the system. They hope to proceed to human trials after collecting initial data, but Bowles believes it could be about 10 years before this method is used in patients.
-end-
Other researchers on the team include University of Utah orthopaedic surgeon Brandon Lawrence, Duke University biomedical engineering associate professor Charles. A. Gersbach, biomedical engineering professor Farshid Guilak and Distinguished Professor Lori A. Setton of Washington University in St. Louis.

This news release and photos may be downloaded from: unews.utah.edu

University of Utah

Related Gene Therapy Articles:

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.
Using gene therapy to treat chronic traumatic encephalopathy
A new study shows the feasibility of using gene therapy to treat the progressive neurodegenerative disorder chronic traumatic encephalopathy (CTE).
New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.
Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.
Non-viral gene therapy to speed up cancer research
A new treatment method promises to speed up gene therapy research and could bring new, patient friendly cancer treatments to market faster.
Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.
Gene therapy for blood disorders
Delivering gene-regulating material to cells that live deep in our bone marrow and direct the formation of blood cells.
Realizing the potential of gene therapy for neurological disorders
Promising findings from preclinical animal studies show the potential of gene therapy for treating incurable neurological disorders.
Gene therapy vectors carrying the telomerase gene do not increase the risk of cancer
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.
Study advances gene therapy for glaucoma
In a study published today in the scientific journal Investigative Ophthalmology and Visual Science, Kaufman and Curtis Brandt, a fellow professor of ophthalmology and visual sciences at UW-Madison, showed an improved tactic for delivering new genes into the eye's fluid drain, called the trabecular meshwork.
More Gene Therapy News and Gene Therapy Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.